(310 days)
Not Found
No
The 510(k) summary describes a topical cream and does not mention any AI or ML components or functionalities.
Yes
The intended use states that Tetrix™ Cream is indicated to "manage and relieve" symptoms of various dermatoses and "helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process." These actions directly address a medical condition and promote healing, fitting the definition of a therapeutic device.
No
The device, Tetrix™ Cream, is described as a cream formulation indicated to manage and relieve symptoms of various dermatoses and help relieve dry skin. It is used for treatment and symptom management, not for diagnosing a condition.
No
The device description clearly states it is a "non-sterile cream formulation," indicating it is a physical product, not software.
Based on the provided information, Tetrix™ Cream is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to manage and relieve symptoms of dermatoses (skin conditions) by being applied topically to the skin. This is a direct application to the body, not a test performed on a sample taken from the body.
- Device Description: It is described as a "non-sterile cream formulation intended for prescription use only." This further reinforces its nature as a topical treatment.
- Lack of IVD Characteristics: The description does not mention any of the typical characteristics of an IVD, such as:
- Analyzing samples (blood, urine, tissue, etc.)
- Providing diagnostic information based on the analysis of samples
- Using reagents or other components for in vitro testing
In summary, Tetrix™ Cream is a topical medical device intended for the treatment of skin conditions, not for performing diagnostic tests on samples outside of the body.
N/A
Intended Use / Indications for Use
Tetrix™ Cream is indicated to manage and relieve the burning and itching experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Tetrix™ Cream helps to relieve dry, waxy skun by mains and moist wound and skin environment, which is beneficial to the healing process.
Product codes
FRO
Device Description
Tctrix™ Cream is a non-sterile cream formulation intended for prescription use only,
Clinical studies provided evidence that Tetrix™ Cream prevents nickel salts, neomycin and a mixture of fragrances from making contact with the skin. Please see clinical studies section.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Functional and performance testing has been conducted to assess the safety and effectiveness of Tetrix™ Crcam and the results are satisfactory.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
page 1/2
CONFIDENTIA Updated 510(k) Summary
Section 2 - 510(k) Summary
APR - 4 2008
2.1 Submission Applicant & Correspondent
Applicant: Coria Laboratories, Ltd. 3909 Hulen St. . Fort Worth, TX 76107
Contact: Amy Campbell Phone: (817) 302-3901
2.2 Name of Device
Proprietary Namc: Tetrix TM Cream Common Name: Dressing, wound and burn, hydrogen w/drug and/or biologic Classification Name: Dressing, wound and burn, hydrogen w/drug and/or biologic
Devices to Which New Device is Substantially Equivalent 2.3
| Sinclair Wound | K024367 marketed as AtopiClair™ and Skin
Emulsion Nonsteroidal Cream |
|----------------|-------------------------------------------------------------------------|
| Mimyx™ Cream | K041342 |
2.4 Device Description
Tctrix™ Cream is a non-sterile cream formulation intended for prescription use only,
Clinical studies provided evidence that Tetrix™ Cream prevents nickel salts, neomycin and a mixture of fragrances from making contact with the skin. Please see clinical studies section.
2.5 Intended Use of the Device
Tetrix™ Cream is indicated to manage and relieve the burning and itching experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. TetrixTM Cream helps to relieve dry, waxy skin by maintaining a moist wound and skin cnvironment, which is beneficial to the healing process.
1
K071483 page 2/2
Coria Laboratories, Ltd. 510(k) K071483: Tetrix™ Crcam
CONFIDENTIAL Updated 510(k) Summary
Summary of Technological Characteristics of the Device Compared to the Predicate 2.6 Devices
All products referenced are non sterile cmulsion/gel types that are applied topically to manage the symptoms of various types of dermatoses.
2.7 Tests and Conclusions
Functional and performance testing has been conducted to assess the safety and effectiveness of Tetrix™ Crcam and the results are satisfactory.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with outstretched wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" is arranged in a circular pattern around the emblem.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
APR - 4 2008
Coria Laboratories, Ltd. % Healthpoint, Ltd. Ms. Amy Campbell 3909 Hulen Street Fort Worth, Texas 76107
Re: K071483
Trade/Device Name: Tetrix Cream Regulatory Class: Unclassified Product Code: FRO Dated: April 3, 2008 Received: April 3, 2008
Dear Ms. Campbell:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice. labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Ms. Amy Campbell
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Complion,s at . (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events. (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistances at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Mark M. Mulhern
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K071483
Device Name: Tetrix™ Cream
Indications For Use:
Tetrix™ Cream is indicated to manage and relieve the burning and itching experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Tetrix™ Cream helps to relieve dry, waxy skun by mains and moist wound and skin environment, which is beneficial to the healing process.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Far me
Division of General, Restorative,
and Neurological Devices
Page 1 of
510(k) Number K071483